W Nathaniel Brennen

List of Publications by Year
in descending order

39	1,734	19	37
papers	citations	h-index	g-index

394286

330025

43	43	43	3082
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	There are gremlins in prostate cancer. Nature Cancer, 2022, 3, 530-531.	5.7	0
2	Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy, 2021, 13, 155-175.	1.0	12
3	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases, 2021, 24, 220-232.	2.0	3
4	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight, 2021, 6, .	2.3	22
5	Characterization of tumorâ€associated macrophages in prostate cancer transgenic mouse models. Prostate, 2021, 81, 629-647.	1.2	10
6	Abstract 2896: Effects of hypoxia on normal prostate fibroblast and prostate cancer associated fibroblast metabolism and matrix degradation. , 2021, , .		1
7	Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Research, 2021, 81, 5948-5962.	0.4	30
8	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene, 2020, 39, 6935-6949.	2.6	60
9	A hemiâ€spleen injection model of liver metastasis for prostate cancer. Prostate, 2020, 80, 1263-1269.	1.2	7
10	Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer. Molecular Cancer Therapeutics, 2020, 19, 2353-2362.	1.9	2
11	Stromal CAVIN1 Controls Prostate Cancer Microenvironment and Metastasis by Modulating Lipid Distribution and Inflammatory Signaling. Molecular Cancer Research, 2020, 18, 1414-1426.	1.5	19
12	Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian Journal of Urology, 2019, 6, 99-108.	0.5	15
13	Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research, 2019, 79, 3636-3650.	0.4	47
14	In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cellâ€Based Drug Delivery. Stem Cells Translational Medicine, 2019, 8, 739-740.	1.6	1
15	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine, 2019, 8, 441-449.	1.6	50
16	Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine, 2019, 7, S311-S311.	0.7	6
17	Tumorâ€infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?. Prostate, 2019, 79, 320-330.	1.2	58
18	The what, when, and why of human prostate cancer xenografts. Prostate, 2018, 78, 646-654.	1.2	14

#	Article	IF	Citations
19	Mesenchymal stem cells and the embryonic reawakening theory of BPH. Nature Reviews Urology, 2018, 15, 703-715.	1.9	27
20	Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine, 2018, 7, 651-663.	1.6	192
21	Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Scientific Reports, 2018, 8, 7189.	1.6	41
22	PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget, 2018, 9, 22436-22450.	0.8	5
23	Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy. Cancer Cell, 2017, 32, 399-401.	7.7	15
24	Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer. Cell Cycle, 2017, 16, 1639-1640.	1.3	14
25	Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget, 2017, 8, 46710-46727.	0.8	25
26	Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate, 2016, 76, 552-564.	1.2	21
27	Iterative design of emetineâ€based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Prostate, 2016, 76, 703-714.	1.2	22
28	A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials, 2016, 91, 140-150.	5.7	68
29	Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. Oncotarget, 2016, 7, 71298-71308.	0.8	17
30	Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy. PLoS ONE, 2015, 10, e0129103.	1.1	7
31	Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)â€activated prodrug in murine xenograft models of human cancer. Prostate, 2014, 74, 1308-1319.	1.2	24
32	Enhancement of the T-cell Armamentarium as a Cell-Based Therapy for Prostate Cancer. Cancer Research, 2014, 74, 3390-3395.	0.4	2
33	Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer, 2013, 20, R269-R290.	1.6	57
34	Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer. Oncotarget, 2013, 4, 106-117.	0.8	75
35	Rationale Behind Targeting Fibroblast Activation Proteinâ€“Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy. Molecular Cancer Therapeutics, 2012, 11, 257-266.	1.9	204
36	Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug. Journal of the National Cancer Institute, 2012, 104, 1320-1334.	3.0	155

#	Article	IF	Citations
37	Engineering a Prostate-Specific Membrane Antigenâ€“Activated Tumor Endothelial Cell Prodrug for Cancer Therapy. Science Translational Medicine, 2012, 4, 140ra86.	5.8	187
38	Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics, 2009, 8, 1378-1386.	1.9	138
39	Fibroblast Activation Protein Peptide Substrates Identified from Human Collagen I Derived Gelatin Cleavage Sites. Biochemistry, 2008, 47, 1076-1086.	1.2	76